Neuroprotection by the metabolic antioxidant α-lipoic acid

Free Radical Biology and Medicine

Volumn 22, Issue 1-2, 1997, Pages 359-378

  Packer, Lester ^a   Tritschler, Hans J ^b   Wessel, Klaus ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ASTA MEDICA AG   (Germany)

Author keywords

1, 2 Dithiolane 3 pentanoic acid; 6,8 Dithiooctanoic acid; Antioxidant; Dihydrolipoic acid; Free radicals; Ischemia; Neuroprotection; Thioctic acid; Lipoate; Lipoic acid

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; DIHYDROLIPOATE; EXCITATORY AMINO ACID; NEUROTRANSMITTER; THIOCTIC ACID;

ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; DEGENERATIVE DISEASE; ELECTRON TRANSPORT; HYPOTHESIS; ISCHEMIA; NEUROPROTECTION; NEUROTRANSMISSION; OXIDATIVE STRESS; PRIORITY JOURNAL;

ANIMALIA;

EID: 0029909010     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(96)00269-9     Document Type: Article

References (215)

1. Diem K., Lentner C. Documenta Geigy scientific tables. 1970;J. R. Geigy S.A. Basle, Switzerland.
2. McArdle W. D., Katch K. I., Katch V. L. Exercise physiology: Energy, nutrition, and human performance. 1986;Lea and Febiger, Philadelphia.
3. Bondy S. C., LeBel C. P. The relationship between exitotoxicity and oxidative stress in the central nervous system. Free Radic. Biol. Med. 14:1993;633-642.
4. Dawson V. L. Nitric oxide: Role in neurotoxicity. Clin. Exp. Pharmacol. Physiol. 22:1995;305-308.
5. +: Implications for neurodegeneration. J. Neurochem. 63:1994;584-591.
6. Haba K., Ogawa K., Mizukawa K., Mori A. Time course of changes in lipid peroxidatin, pre and postsynaptic cholinergic indices, NMDA receptor binding and neuronal death in the gerbil hippocampus following transient ischemia. Brain Res. 40:1990;116-122.
7. Kiedrowski L., Costa E., Wroblewski J. T. Glutamate receptor agonists stimulate nitric oxide synthase in primary cultures of cerebellar granule cells. J. Neurochem. 58:1992;335-341.
8. Dawson V. L., Dawson T. M., London E. D., Bredt D. S., Snyder S. H. Nitric oxide mediates glutamate neurotoxicity in primary cortical culture. Proc. Natl. Acad. Sci. USA. 88:1991;6368-6371.
9. Rauhala P., Moahankumar K. P., Sziraki I., Lin A. M.-Y., Chiueh C. C. S-Nitrosothiols and nitric oxide, but not sodium nitroprusside protects nigrostriatal dopaminergic neurons against iron-induced oxidative stress in vivo. Synapse. 23:1996;58-60.
10. Rauhala, P.; Sziraki, I.; Chiueh, C. C. Peroxidation of brain lipids in vitro: Nitric oxide vs. hydroxyl radicals. Free Radic. Biol. Med. (in press).
11. Schulz J. B., Henshaw D. R., Siwek D., Jenkins B. G., Ferrante R. J., Cipolloni P. B., Kowall N. W., Rosen B. R., Beal M. F. Involvement of free radicals in excitotoxicity in vivo. J. Neurochem. 64:1995;2239-2247.
12. Albin R. L., Greenamyre J. T. Alternative excitoxic hypotheses. Neurology. 42:1992;733-738.
13. Cohen G. The pathobiology of Parkinson's disease: Biochemical aspects of dopamine neuron senescence. J. Neural Transm. Suppl. 19:1983;89-103.
14. Graham D. G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14:1978;633-643.
15. Coyle J. T., Puttfarken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 262:1993;689-695.
16. Fahn S., Cohen G. The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it. Ann. Neurol. 32:1992;804-812.
17. Youdim M. B. H., Ben-Schachar D., Riederer P. Is Parkinson's disease - A progressive siderosis of substantia inigra resulting in iron and melanin induced neurodegeneration? Acta Neurol. Scand. Suppl. 126:1989;47-54.
18. Rump A. F., Klaus W. Evidence for norepinephrine cardiotoxicity mediated by superoxide anion radicals in isolated rabbit hearts. Naunyn Schmiedebergs Arch. Pharmacol. 349:1994;295-300.
19. Louis J. C., Magal E., Varon S. Receptor-mediated toxicity of norepinephrine on cultured catecholaminergic neurons of the rat brain stem. J. Pharmacol. Exp. Ther. 262:1992;1274-1283.
20. Aronovitch J., Godinger D., Czapski G. Hydrogen peroxide dependent oxidative degradation of DNA by copper epinephrine. Free Radic. Res. Commun. 12-13:(2):1991;499-508.
21. Fishman J. B., Rubins J. B., Chen J. C., Dickey B. F., Volicer L. Modification of brain guanine nucleotide-binding regulatory proteins by tryptamine-4,5-dione, a neurotoxic derivative of serotonin. J. Neurochem. 56:1991;1851-1854.
22. Chen J. C., Schnepper P. W., To A., Volicer L. Neurochemical changes in the rat brain after intraventricular administration of tryptamine-4,5-dione. Neuropharmacology. 31:1992;215-219.
23. Koyama I., Jasper H. Amino acid content of chronic undercut cortex of the cat in relation to electrical afterdischarge: Comparison with cobalt epileptogenic lesions. Can. J. Physiol. Pharmacol. 55:1977;523-526.
24. Mori A., Kohno M., Masumizu T., Packer L. α -Guanidinoglutaric acid as a free radical generator. Biochem. Mol. Biol. Int. 37:1995;371-374.
25. Mori A. Biochemistry and neurotoxicology of guanidino compounds: Histroy and recent advances. Pavlov. J. Biol. Sci. 22:1987;85-94.
26. Mori A. Reactive oxygen species and the mechanism of induction of seizure by guanidino compounds. Packer L., Hiramatsu M., Yoshikawa T. Free radicals in brain physiology and disorders. 1996;Academic Press, New York.
27. Koide H., Azuma C. Metabolic profiles of guanidino compounds in various tissues of uriemic rats. Mori A., Cohen B. D., Lowental A. Guanidines - Historical, biological, biochemical and clinical aspects of the naturally occurring Guanidino compounds. 1985;Plenum Press, New York.
28. Boveris A., B C. The mitochondrial generation of hydrogen peroxide: General properties and effect of hyperbaric oxygen. Biochem. J. 134:1973;707-716.
29. Boveris A., Chance B. The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen. Biochem. J. 134:1973;707-716.
30. Nohl H., Jordan W. The mitochondrial site of superoxide formation. Biochem. Biophys. Res. Commun. 138:1986;533-539.
31. Richter C., Park J. W., Ames B. N. Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc. Natl. Acad. Sci. USA. 85:1988;6465-6467.
32. Harman D. Aging: Prospects for further increases in the functional life span. Age. 17:1994;119-146.
33. Saggu H., Cooksey J., Dexter D., Wells F. R., Lees A., Jenner P., Marsden C. D. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J. Neurochem. 53:1989;692-697.
34. Takeshige K., Minakami S. NADH- and NADPH-dependent formation of superoxide amines by bovine heart submitochondrial particles. Biochem. J. 180:1979;129-135.
35. Zaccarato F., Cavallini L., Deana R., Alexandre R. Pathways of hydrogen-peroxide generation in guinea-pig cerebral cortex mitochondria. Biochem. Biophys. Res. Commun. 154:1988;727-734.
36. Tritschler H.-J., Packer L., Medori R. Oxidative stress and mitochondrial dysfunction in neurodegeneration. Biochem. Mol. Biol. Int. 34:1994;169-181.
37. Jenner P., Dexter D. T., Sian J., Schapira A. H., Marsden C. D. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group. Ann. Neurol. Suppl. 32:1992;S82-S87.
38. Dexter D. T., Holley A. E., Flitter W. D., Slater T. F., Wells F. R., Daniel S. E., Lees A. J., Jenner P., Marsden C. D. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study. Movement Disord. 9:1994;92-97.
39. Shoffner J. M., Watts R. L., Juncos J. L., Torroni A., Wallace D. C. Mitochondrial oxidative phosphorylation defects in Parkinson's disease. Ann. Neurol. 30:1991;332-339.
40. Volicer L., Crino P. B. Involvement of free radicals in dementia of the Alzheimer typer: A hypothesis. Neurobiol. Aging. 11:1990;567-571.
41. Wallace D. C., Singh G., Lott M. T., Hodge J., Schurr T. G., Lezza A. M., Elsas L. J. D., Nikoskelainen E. K. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science. 242:1988;1427-1430.
42. Halliwell B., Gutteridge J. M. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem. J. 21:1984;1-14.
43. Gutteridge J. M. Ferrous ions detected in cerebrospinal fluid by using bleomycin and DNA damage. Clin. Sci. 82:1992;315-320.
44. Choi D. W. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1:1988;623-634.
45. Youdim M. B. H. Iron in the brain: Implications for Parkinson's and Alzheimer's diseases. Mt. Sinai J. Med. 55:1988;97-101.
46. Gerlach M., Ben-Shachar D., Riederer P., Youdim M. B. H. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J. Neurochem. 63:1994;793-807.
47. Halliwell B. Reactive oxygen species and the central nervous system. J. Neurochem. 59:1992;1609-1623.
48. Youdim M. B. H. Brain iron. Neurochemical and behavioral aspects. 1988;Taylor and Francis, New York.
49. Sofic E., Riederer P., Heinsen H., Beckmann H., Reynolds G. P., Hebenstreit G., Youdim M. B. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J. Neural. Transm. 74:1988;199-205.
50. Good P. F., Perl D. P., Bierer L. M., Schmeidler J. Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer's disease: A laser microprobe (LAMMA) study. Ann. Neurol. 31:1992;286-292.
51. Smith M. A., Sayre L. M., Monnier V. M., Perry G. Radical AGEing in Alzheimer's disease. Trends Neurosci. 18:1995;172-176.
52. Stocks J., Gutteridge J. M. C., Sharp R. J., Dormandy T. L. The inhibition of lipid autoxidatin by human serum and its relationship to serum proteins and alpha-tocopherol. Clin. Sci. 47:1974;223-233.
53. Mohanakumar K. P., De Bartolomeis A., Wu R.-M., Yeh K. J., Sternberg L., Peng S.-Y., Murphy D. L., Chiueh C. C. Ferrous-citrate complex and nigral degeneration: Evidence for free radical formation and lipic peroxidation. Ann. NY Acad. Sci. 738:1994;392-399.
54. Kreutzberg G. W. Microglia, the first line of defence in brain pathologies. Arzneimittelforschung. 45:1995;357-360.
55. Colton C. A., Gilbert D. L. Production of superoxide anions by a CNS macrophage, the microglia. FEBS Lett. 223:1987;284-288.
56. Colton C. A., Gilbert D. L. Microglia, an in vivo source of reactive oxygen species in the brain. Adv. Neurol. 59:1993;321-326.
57. LeBel C. P., Bondy S. C. Oxygen radicals: Common mediators of neurotoxicity. Neurotoxicol. Teratol. 13:1991;341-346.
58. LeBel C. P., Ali S. F., McKee M., Bondy S. C. Organometal-induced increases in oxygen radical activity: The potential of 2′,7′-dichlorofluorescin diaceteate as an index of neurotoxic damage. Toxicol. Appl. Pharmacol. 104:1990;17-24.
59. Mattia C., LeBel C. P., Bondy S. C. Effect of toluene and its metabolites on cerebral oxygen radical formation. Biochem. Pharmacol. 42:1991;879-882.
60. Cohen G. Oxy-radical toxicity in catecholamine neurons. Neurotoxicology. 5:1984;77-82.
61. Johnson J. D., Conroy W. G., Burris K. D., Isom G. E. Peroxidation of brain lipid following cyanide intoxidation in mice. Toxicology. 46:1987;21-28.
62. Donaldson J., Labelle F. S., Gesser D. Ehanced auto-oxidation of dopamine as a possible basis of manganese neurotoxicity. Neurotoxicology. 2:1981;53-64.
63. Sziraki I., Rauhala P., Chiueh C. C. Novel protective effect of manganese against ferrous citrate-induced lipid peroxidation and nigrostriatal neurodegeneration in vivo. Brain Res. 698:1995;285-287.
64. Ramsay R. R., Youngster S. K., Nicklas W. J., McKeown K. A., Jin Y. Z., Heikkila R. E., Singer T. P. Structural dependence of the inhibition of mitochondrial respiration and of NADH oxidase by 1-methyl-4-phenylpyridinium (MPP+) analogs and their energized accumulation by mitochondria. Proc. Natl. Acad. Sci. USA. 86:1989;9168-9172.
65. Chiueh C. C., Krishna G., Tulsi P., Obata T., Lang K., Huang S.-J., Murphy D. L. Intracranial microdialysis of salicylic acid to detect hydroxyl radical generation through dopamine autoxidation in the caudate nucleus: Effects of MPP+. Free Radic. Biol. Med. 13:1992;581-583.
66. Obata T., Chiueh C. C. In vivo trapping of hydroxyl free radicals in the striatum utilizing intracranial microdialysis perfusion of salicylate: Effects of MPTP, MPDP+ and MPP+. J. Neural Transm. 89:1992;139-145.
67. Wu R.-M., Mohanakumar K. P., Murphy D. L., Chiueh C. C. Antioxidant mechanism and protection of nigral neurons against MPP+ toxicity by deprenyl (selegiline). Ann. NY Acad. Sci. 738:1994;214-222.
68. Chiueh C. C., Miyake H., Peng M. T. Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism. Narabayashi H., Nagatsu T., Yanagisawa N., Mizuno Y. Parkinson's disease: From basic research to treatment. 1993;Raven Press, New York.
69. Chiueh C. C., Huang S.-J., Murphy D. L. Suppression of hydroxyl radical formation by MAO inhibitors: A novel possible neuroprotective mechanism in MPTP neurotoxicity. J. Neural Transm. Suppl. 41:1994;189-196.
70. Mooradian A. D., Smith T. L. The effects of age on lipid composition and order of rat cerebral microvessels. Neurochem. Res. 17:1992;233-237.
71. Bourre J. M. Protection against radical peroxidations in cerebral aging in cerebral capillaries and microvessels. Compt. R. Seances Soc. Biol. Sesfil. 185:1991;5-13.
72. Mattson M. P. Free radicals and disruption of neuronal ion homeostasis in AD: A role for amyloid beta-peptide? Neurobiol. Aging. 16:1995;679-682.
73. Dyrks T., Dyrks E., Hartmann T., Masters C., Beyreuther K. Amyloidogenicity of beta A4 and beta A4-bearing amyloid protein precursor fragments by metal-catalyzed oxidation. J. Biol. Chem. 267:1992;18210-18217.
74. Hensley K., Carney J. M., Mattson M. P., Aksenova M., Harris M., Wu J. F., Floyd R. A., Butterfield D. A. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: Relevance to Alzheimer disease. Proc. Natl. Acad. Sci. USA. 91:1994;3270-3274.
75. Marklund S. L., Westman N. G., Lundgren E., Roos G. Copper- and zinc-containing superoxide dismutase, manganese-containing superoxide dismutase, catalase and glutathione peroxidase in normal and neoplastic human cell lines and normal human tissues. Cancer Res. 42:1982;1955-1961.
76. Delacourte A., Defossez A., Ceballos I., Nicole A., Sinet P. M. Preferential localization of copper zinc superoxide dismutase in the vulnerable cortical neurons in Alzheimer's disease. Neurosci. Lett. 92:1988;247-253.
77. Damier P., Hirsch E. C., Zhang P., Agid Y. A., Javoy-Agid F. Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience. 52:1993;1-6.
78. Benzi G., Moretti A. Age- and peroxidative stress-related modifications of the cerebral enzymatic activities linked to mitochondria and the glutathione system. Free Radic. Biol. Med. 19:1995;77-101.
79. Panigrahi M., Sadguna Y., Shivakumar B. R., Sastry V. R. K., Roy S., Packer L., Ravindranath V. Alpha lipoic acid protects against reperfusion injury following cerebral ischemia in rats. Brain Res. 717:1996;184-188.
80. Gerlach M., Ben-Shachar D., Riederer P., Youdim M. B. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J. Neurochem. 63:1994;793-807.
81. Riederer P., Sofic E., Rausch W. D., Schmidt B., Reynolds G. P., Jellinger K., Youdim M. B. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52:1989;515-520.
82. Orlowski M., Karkowsky A. Glutathione metabolism and some possible functions of glutathione in the nervous system. Int. Rev. Neurobiol. 19:1976;75-121.
83. Holdiness M. R. Clinical pharmacokinetics of N-acetylcysteine. Clin. Pharmacokin. 20:1991;123-134.
84. Flanagan R. J., Meredith T. J. Use of N-acetylcysteine in clinical toxicology. Am. J. Med. 91:1991;131S-139S.
85. Anderson A., Powrie F., Puri R. N., Meister A. Glutathione monoethyl ester: Preparation, uptake by tissues, and conversion to glutathione. Arch. Bioch. Biophys. 239:1985;538-548.
86. Reed L. J., DeBusk B. G., Gunsalus I. C., Hornberger J. C. S. Crystalline α -lipoic acid: A catalytic agent associated with pyruvate dehydrogenase. Science. 114:1951;93-94.
87. Reed L. J. Multienzyme complex. Acc. Chem. Res. 7:1974;40-46.
88. Reed L. J. The chemistry and function of lipoic acids. Adv. Enzymol. 18:1957;319-347.
89. Pick U., Haramaki N., Constantinescu A., Handelman G. J., Tritschler H. J., Packer L. Glutathione reductase and lipoamide dehydrogenase have opposite stereospecificities for α -lipoic acid enantiomers. Biochem. Biophys. Res. Commun. 206:1995;724-730.
90. 2+ in oxidant incuced NF-κB acitivation. FEBS Lett. 385:1996;58-62.
91. Greenamyre J. T., Garcia-Osuna M., Greene J. G. The endogenous cofactors, thioctic acid and dihydrolipoic acid, are neuroprotective against NMDA and malonic acid lesions of striatum. Neurosci. Lett. 171:1994;17-20.
92. Podda M., Tritschler H. J., Ulrich H., Packer L. α -Lipoic acid supplementation prevents symptoms of vitamin E deficiency. Biochem. Biophys. Res. Commun. 204:1994;98-104.
93. Packer L., Witt E. H., Tritschler H. J. Alpha-lipoic acid as a biological antioxidant. Free Radic. Biol. Med. 19:1995;227-250.
94. Whiteman M., Tritschler H. J., Halliwell B. Protection against peroxynitrite-dependent tyrosine nitration and alpha 1-antiproteinase inactivation by oxidized and reduced lipoic acid. FEBS Lett. 397:1996;74-76.
95. Bridges R. J., Koh J. Y., Hatalski C. G., Cotman C. W. Increased excitotoxic vulnerability of cortical cultures with reduced levels of glutathione. Eur. J. Pharmacol. 192:1991;199-200.
96. Busse E., Zimmer G., Schopohl B., Kornhuber B. Influence of alpha-lipoic acid on intracellular glutathione in vitro and in vivo. Arzneimittelforschung. 42:1992;829-831.
97. Han D., Tritschler H. J., Packer L. Alpha-lipoic acid increases intracellular glutathione in a human T-lymphocyte Jurkat cell line. Biochem. Biophys. Res. 207:1995;258-264.
98. Halliwell B., Gutteridge J. M. C. Free radicals in biology and medicine. 2nd ed. 1989;Clarendon Press, Oxford, England.
99. Garthwaite J., Boulton C. L. Nitric oxide signaling in the central nervous system. Annu. Rev. Physiol. 57:1995;683-706.
100. Gross S. S., Wolin M. S. Nitric oxide: Pathophysiological mechanisms. Annu. Rev. Physiol. 57:1995;737-769.
101. 2+-independent nitric oxide synthases. FEBS Lett. 291:1991;145-149.
102. Bredt, D. S. Subcellular targeting of neuronal nitric oxide synthesis. In: Packer, L.; Hiramatsu, M.; Yoshikawa, T. eds. Free radicals in brain physiology and disorders. New York: Academic Press; 1995.
103. Garthwaite J., Garthwaite G. Cellular origins of cyclic GMP responses to excitatory amino acid receptor agonists in rat cerebellum in vitro. J. Neurochem. 48:1987;29-39.
104. Lei S., Pan Z.-H., Aggarwal S. K., Chen H.-S. V., Hartman J., Sucher N. J., Lipton S. A. Effect of nitric oxide production on the redox modulatory site of tne NMDA receptor-channel complex. Neuron. 8:1992;1087-1099.
105. Sen C. K., Packer L. Antioxidant and redox regulation of gene transcription. FASEB J. 10:1996;709-720.
106. Hayashi, T.; Ueno, Y.; Okamoto, T. Oxidoreductive regulation of nuclear factor kappa B. Involvement of a cellular reducing catalyst thioredoxin. J. Biol. Chem. 268:11380-11308; 1993.
107. Baeuerle P. A. The inducible transcription activator NF-κB: Regulation by distinct protein subunits. Biochim. Biophys. Acta. 1072:1991;63-80.
108. Molitor J. A., Ballard D. W., Greene W. C. κB-Specific DNA binding proteins are differentially inhibited by enhancer mutations and biological oxidation. New Biol. 3:1991;987-996.
109. Toledano M. B., Leonard W. J. Modulation of transcription factor NF-κB binding activity by oxidation-reduction in vitro. Proc. Natl. Acad. Sci. USA. 88:1991;4328-4332.
110. Suzuki Y. J., Aggarwal B. B., Packer L. Alpha-lipoic acid is a potent inhibitor of NF-κB activation in human T cells. Biochem. Biophys. Res. Commun. 189:1992;1709-1715.
111. Suzuki Y. J., Mizuno M., Tritschler H. J., Packer L. Redox regulation of NF-κB DNA binding activity by dihydrolipoate. Biochem. Mol. Biol. Int. 36:1995;241-246.
112. Mizuno M., Packer L. Effects of alpha-lipoic acid and dihydrolipoic acid on expression of proto-oncogene c-fos. Biochem. Biophys. Res. Commun. 200:1994;1136-1142.
113. Packer, L. New horizons in antioxidant research: Action of the thioctic acid/dihydrolipoic acid couple in biological systems. In: Schmidt, K.; Ulrich, H., eds. Thioctsäure. 2. Internationl Thioctic Acid Workshop Frankfurt: Universimed Verlag GmbH; 1992:35-44.
114. 14C] α -lipoic acid in selected organs of the rat after single oral and intravenous administration with special respect to nervous tissues. Arzneimittleforsch./Drug Res. (in press).
115. Hermann R., Niebch G., Borbe H. O., Fieger H., Ruus P., Nowak H., Riethmuller-Winzen H., Peujkert M., Blume H. Enantioselective pharmacokinetics and biovailability of different racemic α -lipoic acid formulations in healthy volunteers. Eur. J. Pharm. Sci. 4:1996;167-174.
116. Bromont C., Marie C., Bralet J. Increased lipid peroxidation in vulnerable brain regions after transient forebrain ischemia. Stroke. 20:1989;918-924.
117. Hall E. D., Braughler J. M. Central nervous system trauma and stroke. Free Radic. Med. Biol. 6:1989;303-313.
118. Oliver C. N., Starke-Reed P. E., Stadtman E. R., Liu G. J., Carney J. M., Floyd R. A. Oxidative damage to brain proteins, loss of glutamine synthetase activity, and production of free radicals during ischemia/reperfusion-induced injury to gerbil brain. Proc. Natl. Acad. Sci. USA. 87:1990;5144-5157.
119. Shivakumar B. R., Kolluri K. V. R., Ravindranath V. Glutathione and protein thiol homeostasis in brain during reperfusion following cerebral ischemia. J. Pharmacol. Exp. Ther. 274:1995;1167-1173.
120. Abe Y., Yuki S., Kogure K. Strong attenuation of ischemic and postischemic brain edema in rats by a novel free radical scavenger. Stroke. 19:1988;480-485.
121. Berry K. P., Braughler J. M., Hall E. D. Protection against postischemic mortality and neuronal necrosis in gerbils by the 21-aminosteroid U74006F, a potent inhibitor of lipid peroxidation. Soc. Neurosci. Abstr. 13:1987;1494.
122. Yamamoto M., Shima T., Uozumi T., Sogabe T., Yamada K., Kawasaki T. A possible role of lipid peroxidation in cellular damage caused by cerebral ischemia and the protective effect of α -tocopherol administration. Stroke. 14:1983;977-982.
123. Prehn J. H. M., Karkoutly C., Nuglisch J., Peruche B., Krieglstein J. Dihydrolipoate reduces neuronal injury after cerebral ischemia. J. Cereb. Blood Flow Metab. 12:1992;78-87.
124. Muller U., Krieglstein J. Prolonged pretreatment with alpha-lipoic acid protects cultured neurons against hypoxic, glutamate- or iron-induced injury. J. Cereb. Blood Flow Metab. 15:1995;624-630.
125. Prehn J. H., Peruche B., Karkoutly C., Roßberg C., Mennel H. D., Krieglstein J. Dihydrolipoic acid protects neurons against ischemic/hypoxic damage. Krieglstein J., Oberpichler H. Pharmacology of cerebral ischemia. 1990;357-362 Wissenschaftliche Verlagsgesellscheaft mbH, Stuttgart.
126. Backhaus C., Karkoutly C., Welsch M., Krieglstein J. A mouse model of focal cerebral ischemia for screening neuroprotective drug effects. J. Pharmacol. Methods. 27:1992;27-32.
127. Cao X., Phillis J. W. The free radical scavenger, α -lipoic acid, protects against cerebral ischemia-reperfusion injury in gerbils. Free Radic. Res. 23:1995;365-370.
128. Bast A., Haenen G. R. M. M. Regulation of lipid peroxidation of glutathione and lipoic acid: Involvement of liver microsomal vitamin E free radical reductase. Emerit I., Packer L., Auclair C. Antioxidants in therapy and preventive medicine. 1990;111-116 Plenum Press, New York.
129. Kagan V., Shvedova A., Serbinova E., Khan S., Swanson C., Powell R., Packer L. Dihydrolipoic acid - A universal antioxidant both in the membrane and in the aqueous phase. Reduction of peroxyl, ascorbyl and chromanoxyl radicals. Biochem. Pharmacol. 44:1992;1637-1649.
130. Kagan V. E., Serbinova E. A., Forte T., Scita G., Packer L. Recycling of vitamin E in human low density lipoproteins. J. Lipid Res. 33:1992;385-397.
131. Gotz M. E., Dirr A., Burger R., Wanetzky B., Weinmuller M., Chan W. W., Chen S. C., Reichmann H., Rausch W. D., Riederer P. Effect of lipoic acid on redox state of coenzyme Q in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and diethyldithiocarbamate. Eur. J. Pharmacol. 266:1994;291-300.
132. Kagan V., Serbinova E., Packer L. Antioxidant effects of ubiquinones in microsomes and mitochondria are mediated by tocopherol recycling. Biochem. Biophys. Res. Commun. 169:1990;851-857.
133. Bast A., Haenen G. R. M. M. Interplay between lipoic acid and glutathione in the protection against microsomal lipid peroxidation. Biochim. Biophys. Acta. 963:1988;558-561.
134. Gleason F. K., Holmgren A. Thioredoxin and related protein in procaryotes. FEMS Microbiol. Rev. 54:1988;271-297.
135. Holmgren A. Thioredoxin catalyzes the reduction of insulin disulfides by tithiothreitol and dihydrolipoamide. J. Biol. Chem. 254:1979;9627-9632.
136. Carney J. M., Starke-Reed P. E., Oliver C. N., Landum R. W., Cheng M. S., Wu J. F., Floyd R. R. Reversal of age-related increase in brain protein oxidation, decrease in enzyme activity and loss in temporal and spatial memeory, by chronic administration of the spin trapping compound N-tert-butyl-a-phenylnitrone. Proc. Nat. Acad. Sci. USA. 88:1988;233-238.
137. Stoll S., Hartmann H., Cohen S. A., Müller W. E. The potent free radical scavenger α -lipoic acid improves memory in aged mice: Putative relationship to NMDA receptor deficits. Pharmacol. Biochem. Behav. 46:1993;799-805.
138. Stoll S., Rostock A., Bartsch R., Korn E., Meichelbock A., Muller W. E. The potent free radical scavenger alpha-lipoic acid improves cognition in rodents. Ann. NY Acad. Sci. 717:1994;122-128.
139. Tang L.-H., Aizenman E. Allosteric modulation of the NMDA receptor by dihydrolipoic acid and lipoic acid in rat cortical neurons in vitro. Neuron. 11:1993;857-863.
140. Bunik V. I., Buneeva O. A., Gomazkova V. S. Change in α -ketoglutarate dehydrogenase cooperative properties due to dihydrolipoate and NADH. FEBS Lett. 269:1990;252-254.
141. Zimmer G., Mainka L., Kruger E. Dihydrolipoic acid activates oligomycin-sensitive thiol groups and increases ATP synthesis in mitochondria. Arch. Biochem. Biophys. 288:1991;609-613.
142. Ben-Shachar D., Riederer P., Youdim M. B. H. Iron-melanin interaction and lipid peroxidation: Implications for Parkinson's disease. J. Neurochem. 57:1991;1609-1614.
143. Spencer J. P. E., Jenner A., Butler J., Aruoma O. I., Dexter D. T., Jenner P., Halliwell B. Evaluation of the pro-oxidant and antioxidant actions of L-DOPA and dopamine in vitro: Implications for Parkinson's disease. Free Radic. Res. 24:1996;95-105.
144. Parker W. D. J., Boyson S. J., Parks J. K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26:1989;719-723.
145. Lestienne P., Nelson J., Riederer P., Jellinger K., Reichmann H. Normal mitochondrial genome in brain from patients with Parkinson's disease and complex I defect. J. Neurochem. 55:1990;1810-1812.
146. Chiueh C. C., Miyake H., Peng M.-T. Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced Parkinsonism. Adv. Neurol. 60:1993;251-258.
147. Nicklas W. J., Vyas I., Heikkila R. E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36:1985;2503-2508.
148. Dexter D. T., Carayon A., Javoy-Agid F., Agid Y., Wells F. R., Daniel S. E., Lees A. J., Jenner P., Marsden C. D. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain. 114:1991;1953-1975.
149. Perry T. L., Godin D. V., Hansen S. Parkinson's disease: A disorder due to nigral glutathione deficiency? Neurosci. Lett. 33:1982;305-310.
150. Sian J., Dexter D. T., Lees A. J., Daniel S., Agid Y., Javoy-Agid F., Jenner P., Marsden C. D. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 36:1994;348-355.
151. Ogawa N., Edamatsu R., Mizukawa K., Asanuma M., Kohno M., Mori A. Degeneration of dopaminergic neurons and free radicals: Possible participation of levodopa. Adv. Neurol. 60:1993;242-250.
152. Ogawa N., Asanuma M., Kondo Y., Kawada Y., Yamamoto M., Mori A. Differential effects of chronic L-DOPA treatment on lipid peroxidation in the mouse brain with or without pretreatment with 6-hydroxydopamine. Neurosci. Lett. 17:1994;55-58.
153. Spencer J. P. E., Jenner P., Halliwell B. Superoxide-dependent depletion of reduced glutathione by L-DOPA and dopamine. Relevance to Parkinson's disease. Neuroreport. 6:1995;1480-1484.
154. Gotz M. E., Kunig G., Riederer P., Youdim M. B. H. Oxidative stress: Free radical production in neural degeneration. Pharmacol. Ther. 63:1994;37-122.
155. Effect of deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 321:1989;1364-1371.
156. Koutsillieri, E.; Gotz, M. E.; Riederer, P.; Rausch, W.-D. Effect of lipoic acid on primary neuronal cultures treated with 1-methyl-4-phenylpyridinium. Neural Transm.
157. 14C-deoxyglucose incorporation in rat brain following treatment with α -lipoic acid. Diab. Stoffw. (in press).
158. Porrino L. J., Burns R. S., Crane A. M., Palambo E., Kopin I. J., Sokoloff L. Changes in local cerebral glucose utilisation associated with Parkinson's syndrome induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the primate. Life Sci. 40:1987;1657-1664.
159. Ben-Sachar D., Eshel G., Finberg J. P., Youdim M. B. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 56:1991;1441-1444.
160. Ogawa N., Tanaka K., Asanuma M., Kawai M., Masumizu T., Kohno M., Mori A. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res. 657:1994;207-213.
161. Chiueh C. C., Murphy D. L., Miyake H., Land K., Tulsi P. K., Huang S.-J. Hydroxyl free radical (·OH) formation reflected by salicylate hydroxylation and neuromelanin: In vivo markers for oxidative injury of nigral neurons. Ann. NY Acad. Sci. 679:1993;370-375.
162. Seaton T. A., Jenner P., Marsden C. D. Thioctic acid does not restore glutathione levels or protect against the potentiation of 6-hydroxydopamine toxicity induced by glutathione depletion in rat brain. Neural Transm. 103:1996;315-329.
163. Kish S. J., Bergeron C., Rajput A., Dozic S., Mastrogiacomo F., Chang L. J., Wilson J. M., DiStefano L. M., Nobrega J. N. Brain cytochrome oxidase in Alzheimer's disease. J. Neurochem. 59:1992;776-779.
164. Parker W. D. J., Parks J., Filley C. M., Kleinschmidt-DeMasters B. K. Electron transport chain defects in Alzheimer's disease brain. Neurology. 44:1994;1090-1096.
165. Subbarao K. V., Richardson J. S., Ang L. C. Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J. Neurochem. 55:1990;342-345.
166. Buee L., Hof P. R., Bouras C., Delacourte A., Perl D. P., Morrison J. H., Fillit H. M. Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders. Acta Neuropathol. 87:1994;469-480.
167. Butterfield D. A., Hensley K., Hall N., Subramaniam R., Howard B. J., Cole P., Yatin S., LaFontaine M., Harris M. E., Aksenova M., Aksenov M., Carney J. M. β -Amyloid-derived free radical oxidation: A fundamental process in Alzheimer's disease. Tanzi R. E., Wasco W. Molecular models of dementia. 1996;Humana Press, New York.
168. Choi B. H. Oxidative stress and Alzheimer's disease. Neurobiol. Aging. 16:1995;675-678.
169. Low P. A., Nickander K. K. Oxygen free radical effects in sciatic nerve in experimental diabetes. Diabetes. 40:1991;873-877.
170. Cameron N. E., Cotter M. A., Archibald V., Dines K. C., Maxfield E. K. Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in nondiabetic and streptozotocin-diabetic rats. Diabetologia. 37:1994;449-459.
171. Bravenboer B., Kappelle A. C., Hamers F. P. T., van Buren T., Erkelens D. W., Gispen W. H. Potential use of glutathione for the prevention and treatment of diabetic neuropathy in the streptozotocin-induced diabetic rat. Diabetologia. 35:1992;813-817.
172. Dimpfel W., Spuler M., Pierau F. K., Ulrich H. Thioctic acid induces dose-dependent sprouting of neurites in cultured rat neuroblastoma cells. Dev. Pharmacol. Ther. 14:1990;193-199.
173. Murase K., Hattori A., Kohno M., Hayashi K. Stimulation of nerve growth factor synthesis/secretion in mouse astroglial cells by coenzymes. Biochem. Mol. Biol. Int. 30:1993;615-621.
174. Bashan N., Burdett E., Klip A. Effect of thioctic acid on glucose transport. Third international thioctic acid workshop. 1993;218-223 Universimed Verlag, Frankfurt, Germany.
175. Ou P., Tritschler H., Wolff S. P. Thioctic (lipoic) acid: A therapeutic metal-chelating antioxidant? Biochem. Pharmacol. 50:1995;123-126.
176. Wolff S. P. Diabetes mellitus and free radicals. Br. Med. Bull. 49:1993;642-652.
177. Nagamatsu M., Nickander K. K., Schmelzer J. D., Raya A., Wittrock D. A., Tritschler H., Low P. A. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care. 18:1995;1160-1167.
178. Sachse G., Willms B. Efficacy of thioctic acid in the therapy of peripheral diabetic neuropathy. Gries F. A., Freund H. J., Rabe F., Berger H. Aspects of autonomic neuropathy in diabetes. 1980;105-108 G. Thieme, New York.
179. Ziegler D., Mayer P., Muhlen H., Gries F. A. Effeckte einer Therapie mit
180. Kähler W., Kuklinski B., Ruhlmann C., Plotz C. Diabetes mellitus - A free radical-associated disease. Effects of adjuvant supplementation of antioxidants. Gries F. A., Wessel K. The role of anti-oxidants in diabetes mellitus: Oxygen radicals and anti-oxidants in diabetes. 1993;33-53 pmi Verl.-Gruppe, Frankfurt am Main.
181. Ziegler D., Hanefeld M., Ruhnau K. J., Meisner H. P., Lobisch M., Schutte K., Gries F. A. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant α -lipoic acid. Diabetologia. 38:1996;1425-1433.
182. Schmidt A. M., Hori O., Chen J. X., Li J. F., Crandall J., Zhang J., Cao R., Yan S. D., Brett J., Stern D. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J. Clin. Invest. 96:1995;1395-1403.
183. Suzuki Y. J., Packer L. Inhibition of NF-κB transcription factor by catechol derivatives. Biochem. Mol. Biol. Int. 32:1994;299-305.
184. Suzuki Y. J., Mizuno M., Packer L. Signal transduction for NF-κB activation: Proposed location of antioxidant-inhibitable step. J. Immunol. 153:1994;5008-5015.
185. Suzuki Y. J., Packer L. Alpha-lipoic acid is a potent inhibitor of NF-kappa B activation in human T cells: Does the mechanism involve antioxidant activities. Packer L., Cadenas E. Biological oxidants and antioxidants. 1994;Hippokrates Verlag, Stuttgart.
186. Sernau T., Bierhaus A., Tritschler H., Ziegler R., Wahl P., Nawroth P. P. Thioctic acid prevents AGE mediate TF inductin by blocking translocation of NF-κB in vitro and in vivo. Arch. Pharmacol. S351:1995;R91.
187. Haugaard N., Haugaard E. S. Stimulation of glucose utilization by thioctic acid in rat diaphragm incubated in vitro. Biochim. Biophys. Acta. 222:1970;583-586.
188. Henriksen E. J., Jacob S., Tritschler H., Wellel K., Augustin H. J., Dietze G. J. Chronic thioctic acid treatment increases insulin-stimulated glucose transport activity in skeletal muscle of obese Zucker rats. Diabetes Suppl. 1:1994;122A.
189. Jacob S., Henriksen E. J., Tritschler H. J., Clancy D. E., Simon I., Schiemann A. L., Ulrich H., Jung I., Dietze G. J., Augustin H. J. Enhancement of glucose disposal in patients with type 2 diabetes by alpha-lipoic acid. Arzneimittelforschung. 45:1994;872-874.
190. Blass J. P. Inborn errors of pyruvate metabolism. Stanbury J. B., Wyngaarden J. B., Fredrickson D. S., Goldstein J. L., Brown M. S. The metabolic basis of inherited disease. 1983;193-203 McGraw Hill, New York.
191. Matalon R., Stumpf D. A., Michals K., Hart R. D., Parks J. K., Goodman S. I. Lipoamide dehydrogenase deficiency with primary lactic acidosis: Favorable response to treatment with oral lipoic acid. J. Pediatr. 104:1984;65-69.
192. Byrd D. J., Krohn H. P., Winkler L., Steinborn C., Hadam M., Brodehl J., Hunneman D. H. Neonatal pyruvate dehydrogenase deficiency with lipoate responsive lactic acidaemia and hyperammonaemia. Eur. J. Pediatr. 148:1989;543-547.
193. Maesaka H., Komiya K., Misugi K., Tada K. Hyperalaninemia, hyperpyruvicemia and lactic acidosis due to pyruvate carboxylase deficiency of the liver; Treatment with thiamine and lipoic acid. Eur. J. Pediatr. 122:1976;159-168.
194. Hommes F. A., Polman m. H. A., Reerink J. D. Leigh's encephalomyelopathy: An inborn error of gluconeogenesis. Arch. Dis. Childhood. 43:1968;423-426.
195. Clayton B. E., Dobbs R. H., Patrick A. D. Leigh's subacute necrotizing encephalopathy: Clinical and biochemical study, with special reference to therapy with lipoate. Arch. Dis. Childhood. 42:1967;467-478.
196. Haworth J. C., Perry T. L., Blass J. P., Hansen S., Urquhart N. Lactic acidosis in three sibs due to defects in both pyruvate dehydrogenase and α -ketoglutarate dehydrogenase complexes. Pediatrics. 58:1976;564-572.
197. Tsuchiyama A., Oyanagi K., Hirano S., Tachi H., Sogawa H., Wagatsuma K., Nakao T., Tsugawa S., Kawamura Y. A case of pyruvate carboxylase deficiency with later prenatal diagnosis of an unaffected sibling. J. Inher. Metab. Dis. 6:1983;85-88.
198. Ohtake M., Takada G., Miyabayashi S., Arai N., Tada K., Morinaga S. Pyruvate decarboxylase deficiency in a patient with Leigh's encephalomyelopathy. Thoku J. Exp. Med. 137:1982;379-386.
199. 31P-MRS in a patient with mitochondrial myopathy. J. Neurol. 242:1995;472-477.
200. Veach R. L., Lawson J. W. R., Cornell N. W., Krebs H. A. Cytosolic phosphorylation potential. J. Biol. Chem. 354:1979;6538-6547.
201. 2+ transport in brain microsomes. Brain Res. 566:1991;127-130.
202. Axelsson B., Dahlgren S. E., Piscator M. Renal lesions in the rabbit after long-term exposure to cadmium. Arch. Environ. Health. 17:1968;24-28.
203. Manca D., Ricard A. C., Trottier B., Chevalier G. Studies on lipid peroxidation in rat tissues following administration of low and moderate doses of cadmium chloride. Toxicology. 67:1991;303-323.
204. Sumathi R., Devi V. K., Varalakshmi P. DL α -lipoic acid protection against cadmium-induced tissue lipid peroxidation. Med. Sci. Res. 22:1994;23-25.
205. Altenkirch H., Stoltenburg-Didinger H., Wagner M., Hermann J., Walter G. Effects of lipoic acid in hexacarbon-induced neuropathy. Neurotoxicol. Teratol. 12:1990;619-622.
206. Tankanow R. M. Pathophysiology and treatment of Wilson's disease. Clin. Pharmacol. 10:1991;839-849.
207. 2+ in solution. Arch. Biochem. Biophys. 187:1978;208-214.
208. da Costa V. S. F. G., Rodrigues E. M., da Silva J. A. F., Relvas M. E. S. A., Halpern M. J. The pathogenesis and therapy of Wilson's disease. Effects of alpha-lipoic acid. Arzeinmittelforschung. 10:1960;333-339.
209. da Costa V. S. F. G., da Silva J. A. F. Therapy of Wilson's disease. Arzneimittelforschung. 13:1963;280-282.
210. da Costa V. S. F. G. Morbus Wilson and the possible therapeutic role of alpha-lipoic acid. Arzneimittleforschung. 20:1970;1210-1213.
211. Asta Medica α -Lipoic acid prescribing information.
212. Shivakumar B. R., Kolluri S. V. R., Ravindranath V. Glutathione and protein thiol homeostasis in brain during reperfusion after cerebral ischemia. J. Pharmacol. Exptl. Therapeutics. 274:1995;1167-1173.
213. Shivakumar B. R., Ravindranath V. Oxidative stress and thiol modification induced by chronic administration of haloperidol. J. Pharmacol. Exptl. Therapeutics. 265:1993;1137-1141.
214. Shivakumar B. R., Ravindranath V. Oxidative stress induced by administration of the neuroleptic drug haloperidol is attenuated by higher doses of haloperidol. Brain Res. 595:1992;256-262.
215. Ravindranath V., Reed D. J. Glutathione depletion and formation of glutathion-protein mixed disulfide following exposure of brain mitochondria to oxidative stress. Bioch. Biophys. Res. Comm. 169:1990;1075-1079.